Position in NTRA
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$16,640,427
+$5,780,571 QoQ
Shares Held
61,302
+12.9% QoQ
Ownership
0.043%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#163
of 847 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 93%
Shared 0%
None 7%
Common Shares in NTRA Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026DANSKE BANK A/S holds $330,700,462 across 14 Diagnostics & Research names. NTRA ranks #5 (5.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
240,911 | $120,783,138 | |
| 2 | DHR |
Danaher Corp /De/
|
325,649 | $62,029,621 | |
| 3 | A |
Agilent Technologies, Inc.
|
245,094 | $32,555,834 | |
| 4 | IDXX |
Idexx Laboratories Inc /De
|
47,228 | $24,862,706 | |
| 5 | NTRA |
Natera, Inc.
This page
|
61,302 | $16,640,427 | |
| 6 | WAT |
Waters Corp /De/
|
42,179 | $15,818,811 | |
| 7 | DGX |
Quest Diagnostics Inc
|
68,561 | $14,531,503 | |
| 8 | IQV |
Iqvia Holdings Inc.
|
73,566 | $14,214,421 |
All Filings in NTRA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,640,427 | 61,302 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $10,859,856 | 54,302 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $13,058,588 | 57,002 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $7,839,560 | 48,702 | Shares | Sole | 2025-11-19 | |
| 2025-06-30 | $8,717,641 | 51,602 | Shares | Sole | 2025-12-18 | |
| 2025-03-31 | $6,716,975 | 47,500 | Shares | Sole | 2025-12-18 | |
| 2024-12-31 | $1,758,870 | 11,111 | Shares | Sole | 2026-03-18 | |
| 2024-09-30 | $495,866 | 3,906 | Shares | Sole | 2026-03-18 | |
| 2024-06-30 | $21,658 | 200 | Shares | Sole | 2026-03-18 | |
| 2024-03-31 | $6,086,205 | 66,545 | Shares | Sole | 2026-03-18 | |
| No filing history on record for this holder in this stock. | ||||||